Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Iparomlimab and Tuvonralimab（QL-1706）Combined With Chemotherapy and Bevacizumab With or Without Radiotherapy as Neoadjuvant Therapy for Locally Advanced Rectal Cancer：A Multicenter, Single Arm Clinical Trial

NCT07769853 is registered in ClinicalTrials.gov with Zhejiang University as lead sponsor.

NCT NCT07769853
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07769853 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Iparomlimab and Tuvonralimab（QL-1706）Combined With Chemotherapy and Bevacizumab With or Without Radiotherapy as Neoadjuvant Therapy for Locally Advanced Rectal Cancer：A Multicenter, Single Arm Clinical Trial
Lead sponsor
Zhejiang University
Phase
Not applicable
Overall status
Not yet recruiting
Start date
September 1, 2026
Completion date
December 12, 2029
Enrollment
56 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

5-12cm to anal verge, locally advanced rectal cancer (larc)